GeneDx's Fourth Quarter Performance Mixed with Joy and Worry

Gathersburg, Maryland - GeneDx Holdings Corp. (NASDAQ: WGS) reported mixed fourth-quarter results, with earnings falling short of expectations but revenue slightly exceeding analyst estimates.

Following the earnings release, the stock declined 0.07% in pre-market trading.

The rare disease diagnostics company posted a fourth-quarter loss of $0.61 per share, well below the analyst consensus of a $0.09 profit per share.

Revenue reached $121 million, slightly above the market expectation of $120.55 million, representing a 27% year-over-year increase. Excluding one-time gains in 2024, the growth was 37%. Compared to $95.3 million in the same quarter last year, this marks significant growth.

GeneDx’s core exome and genome testing revenue grew 32% year-over-year to $104 million, with testing volume accelerating 34% year-over-year to 27,761 tests.

Adjusted gross margin expanded to 71%, up from 70% in the same period last year. However, adjusted net profit decreased from $17.5 million in Q4 2024 to $4.4 million.

“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting too long for answers,” said Katherine Stueland, President and CEO of GeneDx. “Our team is executing at the highest level, our platform continues to expand, and GeneDx’s data advantage is reinforced with each test we perform.”

For fiscal year 2026, GeneDx reaffirmed revenue guidance of $540 million to $555 million, with a midpoint of $547.5 million, slightly above the analyst consensus of $543 million. The company expects exome and genome revenue to grow 33% to 35%, with adjusted gross margins of at least 70%.

For the full fiscal year 2025, revenue totaled $427.5 million, a 41% increase year-over-year, with adjusted net profit of $41.8 million, compared to $9.4 million in 2024.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.